1-20 of 46 results for house:"House of Lords"
Librarians' tools
- Search time
- 0.391 seconds
- Solr query time
- 0.007 seconds
- Search query
- house:"House of Lords"
- We searched for
- legislature_ses:25277
Type
House
Session
Year
Department
Member
More
Primary member
Answering member
Legislative stage
Legislation
Subject
More
Publisher
To ask Her Majesty’s Government whether they intend to publish the report commissioned by the Department of Health on the Cost Effectiveness Methodology for Immunisation Programmes and Procurement, and if so, when.
To ask Her Majesty’s Government whether they intend to publish the report commissioned by the Department of Health on the Cost Effectiveness Methodology for Immunisation Programmes and Procurement, and if so, when.
The Department will be publishing the Cost Effectiveness Methodology for Immunisation Programmes and Procurements report in due course. The timetable has not yet been confirmed.
A decision on consultation has not yet been made.
To ask Her Majesty’s Government whether there will be a consultation on changes to the methodology used by the Joint Committee on Vaccination and Immunisation that result either from the report commissioned by the Department of Health on the Cost-Effectiveness Methodology for Immunisation Programmes and Procurement or from the work...
To ask Her Majesty’s Government whether there will be a consultation on changes to the methodology used by the Joint Committee on Vaccination and Immunisation that result either from the report commissioned by the Department of Health on the Cost-Effectiveness Methodology for Immunisation Programmes and Procurement or from the work...
The Department will be publishing the Cost Effectiveness Methodology for Immunisation Programmes and Procurements report in due course. The timetable has not yet been confirmed.
A decision on consultation has not yet been made.
To ask Her Majesty’s Government how much is paid to GP practices for (1) advising a person to have a flu jab, and (2) giving a person the flu jab.
To ask Her Majesty’s Government how much is paid to GP practices for (1) advising a person to have a flu jab, and (2) giving a person the flu jab.
Under the General Medical Services contract, general practitioners (GPs) are paid £9.80 for each dose of influenza vaccination that they administer to patients who are eligible for the vaccination. GPs are not paid for advising patients to have the influenza vaccination.
An Informal Health Council meeting was held in Bratislava on 3-4 October 2016 as part of the Employment, Social Policy, Health and Consumer Affairs (EPSCO) Council formation. Lord Prior, Parliamentary Under-Secretary of State for Health, represented the UK.
Food reformulation
During a discussion about food reformulation, the UK updated Ministers on...
An Informal Health Council meeting was held in Bratislava on 3-4 October 2016 as part of the Employment, Social Policy, Health and Consumer Affairs (EPSCO) Council formation. Lord Prior, Parliamentary Under-Secretary of State for Health, represented the UK.
Food reformulation
During a discussion about food reformulation, the UK updated Ministers on...
To ask Her Majesty’s Government what assessment they have made of how best to evaluate the impact of vaccination programmes to prevent rare diseases of high severity, and in particular the cost-effectiveness of the vaccination of children.
To ask Her Majesty’s Government what assessment they have made of how best to evaluate the impact of vaccination programmes to prevent rare diseases of high severity, and in particular the cost-effectiveness of the vaccination of children.
The Government bases its evaluation of vaccination programmes on the advice of the Joint Committee on Vaccination and Immunisation (JCVI), other expert groups and evidence from a wide range of epidemiologists and other experts. Their considerations include the impact of rare diseases, immunisation, and impacts on children. The methodology used to assess cost-effectiveness of regular (i.e. non-emergency) immunisation programmes is based on published National Institute for Health and Care Excellence guidance Guide to the methods of technology appraisal 2013. A copy of the guidance is attached.
The Cost Effectiveness Methodology for Immunisation Programmes and Procurements (CEMIPP) working group has reviewed whether any changes to the methodology might be appropriate for immunisation and the Government is considering the advice.
To ask Her Majesty’s Government whether the scope of the Cost Effectiveness Methodology for Immunisation Programmes and Procurements working group has shifted from its original purpose, and if so, why.
To ask Her Majesty’s Government whether the scope of the Cost Effectiveness Methodology for Immunisation Programmes and Procurements working group has shifted from its original purpose, and if so, why.
No, the Terms of Reference have not changed.
To ask Her Majesty’s Government how they will ensure consistency between the recommendations of the Cost Effectiveness Methodology for Immunisation Programmes and Procurements working group and those of the Department of Health’s Appraisal Alignment Working Group on similar issues.
To ask Her Majesty’s Government how they will ensure consistency between the recommendations of the Cost Effectiveness Methodology for Immunisation Programmes and Procurements working group and those of the Department of Health’s Appraisal Alignment Working Group on similar issues.
The report of the Cost Effectiveness Methodology for Immunisation Programmes and Procurement (CEMIPP) review was received in the Department on 20 July. The Department is considering this report and its potential implications.
To ask Her Majesty’s Government whether the Cost Effectiveness Methodology for Immunisation Programmes and Procurements working group’s recommendations will be subject to public consultation, and if so, when.
To ask Her Majesty’s Government whether the Cost Effectiveness Methodology for Immunisation Programmes and Procurements working group’s recommendations will be subject to public consultation, and if so, when.
The Department received the Cost Effectiveness Methodology for Immunisation Programmes and Procurements report on 20 July 2016. The report will be published in due course. A decision on consultation has not yet been made.
To ask Her Majesty’s Government whether the Cost Effectiveness Methodology for Immunisation Programmes and Procurements working group’s final report has been provided to the Department of Health, and if so, when that report will be published.
To ask Her Majesty’s Government whether the Cost Effectiveness Methodology for Immunisation Programmes and Procurements working group’s final report has been provided to the Department of Health, and if so, when that report will be published.
The Department received the Cost Effectiveness Methodology for Immunisation Programmes and Procurements report on 20 July 2016. The report will be published in due course. A decision on consultation has not yet been made.
To ask Her Majesty’s Government what assessment they have made of the implications of the Joint Committee on Vaccination and Immunisation (JCVI) operating differently to other health technology assessment bodies, such as NICE, as stated in the minutes of the June JCVI meeting, in the event that the recommendations of...
To ask Her Majesty’s Government what assessment they have made of the implications of the Joint Committee on Vaccination and Immunisation (JCVI) operating differently to other health technology assessment bodies, such as NICE, as stated in the minutes of the June JCVI meeting, in the event that the recommendations of...
The report of the Cost Effectiveness Methodology for Immunisation Programmes and Procurement (CEMIPP) review was received in the Department on 20 July. The Department is considering this report and its potential implications.
To ask Her Majesty’s Government what assessment they have made of the advice by Professors Stanley, Lawler, Graham, and others, to extend HPV vaccinations to boys to curb the spread of throat and other cancers.
To ask Her Majesty’s Government what assessment they have made of the advice by Professors Stanley, Lawler, Graham, and others, to extend HPV vaccinations to boys to curb the spread of throat and other cancers.
The Joint Committee on Vaccination and Immunisation, the expert committee that advises Ministers on immunisation related issues, is currently in the process of considering the impact and cost-effectiveness of extending the human papilloma virus (HPV) vaccination to adolescent boys. This includes assessing all the necessary evidence and information on the potential impact of a boys vaccination programme on non-cervical cancers caused by HPV.
To ask Her Majesty’s Government what was the total combined overall spending on vaccines procurement and administration (1) nationally, and (2) locally, including awareness campaigns, in each year from 2012–13 to the current financial year.
To ask Her Majesty’s Government what was the total combined overall spending on vaccines procurement and administration (1) nationally, and (2) locally, including awareness campaigns, in each year from 2012–13 to the current financial year.
Public Health England (PHE) and NHS England were formed on 1 April 2013, therefore spend information can only be provided from 2013/2014 financial year onwards. Total combined spend for 2015/16 is not yet available.
Overall spend on procurement and the administration of vaccines, including communications spend for campaigns, is split between PHE and NHS England. The total combined overall spend can only be provided at a national level. Local level information is not readily available. Spend information is provided in the following table.
Approximate combined vaccine procurement and vaccine administration spend for England
Financial Year | 2013/2014 | 2014/2015 |
Vaccine procurement and vaccine administration spend (£ million) | 578 | 616 |
To ask Her Majesty’s Government when they expect the final report of the Cost Effectiveness Methodology for Immunisation Programmes and Procurements working group to be published, and whether its recommendations will be subject to public consultation.
To ask Her Majesty’s Government when they expect the final report of the Cost Effectiveness Methodology for Immunisation Programmes and Procurements working group to be published, and whether its recommendations will be subject to public consultation.
The Government expects to receive the Cost Effectiveness Methodology for Immunisation Programmes and Procurement report shortly and will consider its recommendations once received. Until then, it would not be appropriate to speculate on possible recommendations or the impact they might have. We are committed to publishing their report. We will decide when to publish, and whether to consult, once we have had time to consider the report.
To ask Her Majesty’s Government what assessment they have made of the risk that changes to the cost effectiveness threshold for vaccines as proposed by the Cost Effectiveness Methodology for Immunisation Programmes and Procurements working group would lead to England being restricted from paying for some new vaccines when compared...
To ask Her Majesty’s Government what assessment they have made of the risk that changes to the cost effectiveness threshold for vaccines as proposed by the Cost Effectiveness Methodology for Immunisation Programmes and Procurements working group would lead to England being restricted from paying for some new vaccines when compared...
The Government expects to receive the Cost Effectiveness Methodology for Immunisation Programmes and Procurement report shortly and will consider its recommendations once received. Until then, it would not be appropriate to speculate on possible recommendations or the impact they might have. We are committed to publishing their report. We will decide when to publish, and whether to consult, once we have had time to consider the report.
To ask Her Majesty’s Government what is their assessment of the Nordic Cochrane Centre complaint to the European Medicines Agency (EMA) over maladministration at the EMA dated 26 May in relation to the EMA report on the safety of human papilloma virus vaccine.
To ask Her Majesty’s Government what is their assessment of the Nordic Cochrane Centre complaint to the European Medicines Agency (EMA) over maladministration at the EMA dated 26 May in relation to the EMA report on the safety of human papilloma virus vaccine.
Whilst the issues raised in the Nordic Cochrane Centre document are a matter for the European Medicines Agency (EMA), we are satisfied that the EMA has adequate processes in place to manage any potential conflicts of interest of its scientific experts and to uphold the integrity and impartiality of its decision-making. There was consensus agreement amongst European Union Member States on the conclusions of the recent human papilloma virus vaccine safety review, and we have confidence in the outcome of this review.
My hon. Frriend the Parliamentary Under-Secretary of State (Jane Ellison) has made the following Written Ministerial Statement:
I am today announcing that a human papillomavirus (HPV) vaccination pilot for men who have sex with men (MSM) will start this June.
Since 2008, an HPV vaccination programme for girls has been delivered to...
My hon. Frriend the Parliamentary Under-Secretary of State (Jane Ellison) has made the following Written Ministerial Statement:
I am today announcing that a human papillomavirus (HPV) vaccination pilot for men who have sex with men (MSM) will start this June.
Since 2008, an HPV vaccination programme for girls has been delivered to...
To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 26 April (HL7576), why the current section 7a public health functions agreement does not include performance indicators for the provision of pneumococcal vaccination to severely immunocompromised children aged at least five years and adults,...
To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 26 April (HL7576), why the current section 7a public health functions agreement does not include performance indicators for the provision of pneumococcal vaccination to severely immunocompromised children aged at least five years and adults,...
The performance indicators included in the 2016-17 S7A public health functions agreement do not reflect every activity which is carried out under the agreement.
As I stated in my answer of 26 April, the provision of pneumococcal vaccination to severely immunocompromised children aged at least five years and adults, as recommended by the Joint Committee on Vaccination and Immunisation in July 2013, is reflected in the relevant service specification for the existing pneumococcal immunisation programme and within the document Immunisation against Infectious Diseases (‘the Green Book’). The Green Book is published on the GOV.UK website in an online only format.
A copy of the service specification on the pneumococcal immunisation programme is attached.
To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 21 March (HL7044), why the current section 7a public health functions agreement does not include key deliverables for the provision of pneumococcal vaccination to severely immunocompromised children aged at least five years and adults,...
To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 21 March (HL7044), why the current section 7a public health functions agreement does not include key deliverables for the provision of pneumococcal vaccination to severely immunocompromised children aged at least five years and adults,...
The 2016-17 Section 7A public health functions agreement specifies key deliverables in relation to new or changed programmes that are being introduced within 2016-17.
The provision of pneumococcal vaccination to severely immunocompromised children aged at least five years and adults, as recommended by the Joint Committee on Vaccination and Immunisation in July 2013, is reflected in the relevant service specification for the existing pneumococcal immunisation programme and within the document Immunisation against Infectious Diseases (‘the Green Book’). The Green Book is published on the GOV.UK website in an online only format.
To ask Her Majesty’s Government when the successful tender for the procurement of the human papilloma virus vaccine will be announced.
To ask Her Majesty’s Government when the successful tender for the procurement of the human papilloma virus vaccine will be announced.
Following the conclusion of the contract for the human papilloma virus vaccine, information on the award will be placed in the public domain by way of a notice in the Official Journal of the European Union, and a copy of the contract published on the Contracts Finder website at: www.gov.uk/contracts-finder. We expect to publish both of these by the end of April 2016.
To ask Her Majesty’s Government what plans NHS England has to establish performance floors setting out minimum levels of vaccination coverage in different areas of the country, in line with the commitment in its Putting Patients First business plan.
To ask Her Majesty’s Government what plans NHS England has to establish performance floors setting out minimum levels of vaccination coverage in different areas of the country, in line with the commitment in its Putting Patients First business plan.
NHS England has a specific role to commission those public health services set out in the Section 7A public health functions agreement 2016-17, including immunisation programmes and to hold to account providers to ensure that they deliver the contracts that have been agreed. The agreement sets out specific outputs and outcomes to be achieved by NHS England including performance indicators that outline minimum levels of vaccination coverage for different programmes. NHS England publishes national service specifications outlining the minimum levels of vaccinations expected, which in turn are put into contracts with providers at local level.
The Section 7A agreement requires NHS England to at least maintain, or improve, national levels of performance on existing services, while also implementing planned changes. It also includes an ambition to reduce local variation in performance between different geographical areas.
There are no plans to review incentives, however a number are already in place. For example, within primary care general practitioner (GP) settings, some vaccination services such as flu for those with diabetes have quality outcome framework indicators attached, whereby GPs are rewarded for good practice. Also, as part of the contracts given outside of the primary care settings, local teams can develop Commissioning for Quality and Innovation payments that link a proportion of providers' income to the achievement of local quality improvement goals.